FLT3 and acute myeloid leukemia: Although both type-I and type-II inhibitors are known to be useful for inhibiting FLT3 enzyme activity, recent studies by Wodicka et al.16 have shown that type-I inhibitors bind more strongly to the FLT3-ITD-mutated kinase and hence show more promise as an effective treatment for AML.